BILACO Trial: Biliary Atresia - a Severe Complex Congenital Liver Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-18
SponsorRigshospitalet, Denmark

About this trial

Biliary atresia is the most severe form of cholestatic liver disease. The children have high morbidity and mortality and get devastating pruritus and fatigue, failure to thrive, progressive hepatic failure and impaired neurodevelopment. The etiology is mostly unknown. More than half need a new liver from a living or deceased donor during childhood. However, correct timing of the transplantation is extremely difficult because of lack of consensus based on clinical assessment tools. All though the incidence is low, the cost of this disease is tremendous from both a clinical and human perspective. So far, protocolized neurodevelopment tests, genetic profiling, precise malnutrition evaluation based on clinical appearance, biochemical markers and brain MRI-scans, body composition, immunological function, level of physical activity and optimal time of transplantation in cholestatic children are unknown.

The aim is to determine risk factors for neurocognitive impairment in children suffering from severe cholestasis in order to determine optimal time for liver transplantation from a brain perspective.

In a prospective study, the investigators will investigate risk factors related to brain-, heart-, gut- and immunological function in the Danish cohort. This cohort consists of 75 children aged 0-18 years. In addition, 30 aged and gender matched healthy and 20 tetra fallot children will serve as control groups. The children will undergo extensive and advanced liver function evaluation, genetic profiling, nutrition and immunological status, neuro-imaging and neurocognitive evaluation at time of diagnose, 2 years of age, pre-school, pre-teenage, and teenage. In case of a liver transplantation, additional neuro-cognitive tests will be performed

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Biliary atresia

Tetralogy of Fallot

Healthy controls

Disqualifiers

None

Trial population

Children with biliary atresia (BA), children with Tetralogy of Fallot (ToF) and healthy control children between the age of 0-17 years. The BA and ToF children were recruited from their respective outpatient clinics at Rigshospitalet, Denmark, which is the only centre treating these patients. Healthy controls were siblings to BA children, recruited from staffs children and friends or recruited from a general practitioners office in Nivaa, Denmark. The recruitment took place from March 2020 and is ongoing

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • Neurocognitive monitoring

    Other intervention

    Neurocognitive tests and MRI of the brain

Treatment groups

100 Participants
are divided into 3 treatment groups
Group A: Children with biliary atresia1 intervention
Group B: Children with Tetralogy of Fallot1 intervention
Group C: Healthy control children1 intervention

Trial outcomes

Primary outcomes

1

MRI of the brain

% of patients with anatomic anomalies on MRI of the brain

Time frame
Inclusion
2

Neurocognitive status: Early movement repertoire (General movement)

Neurocognitive test panel depending on age at inclusion % of patients with of abnormal movement assessed using early movement repertoire (GM) if inclusion at diagnosis. Early movement repertoire is a measurement tool where abnormal movement is identified.

Time frame
Inclusion
3

Neurocognitive status: Alberta Infant Motor Scale

Neurocognitive test panel depending on age at inclusion: Alberta Infant Motor Scale if inclusion at diagnosis Percentile, highest is the best

Time frame
Inclusion
4

Neurocognitive status: Bayley Scales of Development III

Neurocognitive test panel depending on age at inclusion: Bayley Scales of Development III if inclusion up to 2.5 years: From 0-200, highest is best

Time frame
Inclusion

Secondary outcomes

1

Genetics: Whole genome sequencing of blood

Whole genome sequencing of blood

Time frame
Inclusion
2

Genetics: Whole genome sequencing of liver biopsy

Whole genome sequencing of liver biopsy

Time frame
Inclusion
3

Microbiome: Urine proteomics

Microbiome measurements on urine

Time frame
Inclusion
4

Microbiome: Feces proteomics

Microbiome measurements on feces

Time frame
Inclusion

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.